6A. These results suggest that S1P and S1P2 contribute, at least in part, to the enhancement of Rho kinase activity in the livers of bile duct-ligated mice. Then liver fibrosis was evaluated in wildtype and S1P mice at 3 weeks following bile duct ligation. RG7204 manufacturer Sirius Red staining of the livers showed that fibrosis developed around bile duct and ductal structures and in lobular septa in wildtype mice, whereas less fibrosis was observed predominantly around ductal structures in S1P mice (Fig. 6B). Smooth-muscle α-actin mRNA expression in the liver was significantly higher in wildtype mice than in S1P mice (Fig. 6C).
Collectively, liver fibrosis induced by bile duct ligation was less prominent in S1P mice than in wildtype mice. Next, an intravenous infusion of S1P2 antagonist at 1 mg/kg body weight was performed in wildtype and S1P mice at 3 weeks following bile duct ligation. The S1P2 antagonist reduced portal vein pressure in wildtype mice, but not in S1P mice
(Fig. 6D). Because previous studies indicate that S1P2 antagonist exerts its effect also on hepatocytes,14, 27 liver enzymes in serum and liver histology were examined at 24 hours after intravenous injection of the S1P2 antagonist (1 mg/kg body weight) in normal rats to examine SAHA HDAC molecular weight whether its intravenous administration might affect hepatocytes. As demonstrated in Fig. 7A-E, serum levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and gamma-glutamyltransferase and liver histology were not altered with intravenous injection of the S1P2 antagonist. In the current study, intravenously administered S1P2 antagonist reduced portal vein pressure without affecting mean arterial pressure in cirrhotic rats caused by bile duct ligation. This effect of the S1P2 antagonist involved the reduction of Rho kinase activity in the liver. On the other hand, the same amount of S1P2 antagonist did not alter portal vein pressure and mean
arterial pressure in control sham rats. Up-regulation of S1P2 expression was observed in the bile duct-ligated livers of rats and mice, predominantly in hepatic stellate cells as smooth-muscle α-actin-expressing cells. Finally, the contribution Astemizole of S1P and S1P2 to the enhancement of Rho kinase activity in the liver as well as the formation of liver fibrosis following bile duct ligation was determined in mice. It is now well known that the intrahepatic up-regulation of Rho kinase signaling plays an important role in the pathophysiology of portal hypertension with increasing hepatic vascular resistance.22 Thus, Rho kinase has become one of the main targets when establishing the treatment strategy for portal hypertension.13, 17, 25, 28 On the other hand, among the S1P receptors it has been shown that S1P2 is specifically coupled to Rho and Rho kinase signaling.
Related posts:
- The continuous Pringle maneuver allows for shorter total occlusio
- 2004) Because this protein forms a latent complex with TGF-��, o
- All results confirm that emodin protected the liver from injury a
- Humans with chronic liver disease were also studied Results: In
- A hepatofugal flow can be changed to a hepatopetal splenic venous